Back to search

Article

Effectiveness of Elbasvir and Grazoprevir Combination and 1-year Follow-up Hepatic Function for HCV Genotype 1b Infection: Results From a Chinese Real-world Cohort.

2020-12-31

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> The treatment of chronic hepatitis C (CHC) has entered the interferon-free era since the approval of all-oral direct-acting antiviral (DAA) therapy in China. Twelve weeks of Elbasvir and Grazoprevir (EBR/GZR) has been demonstrated to be highly effective and well tolerated in phase III registration trials in Asia. However, real-world data on this regimen are lack...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2d06b1f4-1039-5dcf-af45-870deef960f9
DOI
10.21203/rs.3.rs-136726/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effectiveness of Elbasvir and Grazoprevir Combination and 1-year Follow-up Hepatic Function for HCV Genotype 1b Infection: Results From a Chinese Real-world Cohort.DOI 10.21203/rs.3.rs-136726/v1
Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan.Semantic proximity
Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.Semantic proximity
Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.Semantic proximity
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.Semantic proximity
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.Semantic proximity
Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.Semantic proximity
Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.Semantic proximity
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.Semantic proximity
Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.Semantic proximity
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.Semantic proximity
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.Semantic proximity
Chronic Hepatitis C and comorbidities: real-world study to evaluate impact in outcomes after treatment with sofosbuvir-based regimensSemantic proximity
Select a neighboring publication to make it the new centre.